Cargando…

Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s

BACKGROUND: Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren’s syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren’s demonstrate pulmonary involvement with higher mortality and lower quality of life. RESEARCH...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Augustine S., Scofield, R. Hal, Hammitt, Katherine Morland, Gupta, Nishant, Thomas, Donald E., Moua, Teng, Ussavarungsi, Kamonpun, St Clair, E. William, Meehan, Richard, Dunleavy, Kieron, Makara, Matt, Carsons, Steven E., Carteron, Nancy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438162/
https://www.ncbi.nlm.nih.gov/pubmed/33075377
http://dx.doi.org/10.1016/j.chest.2020.10.011
_version_ 1783752310089842688
author Lee, Augustine S.
Scofield, R. Hal
Hammitt, Katherine Morland
Gupta, Nishant
Thomas, Donald E.
Moua, Teng
Ussavarungsi, Kamonpun
St Clair, E. William
Meehan, Richard
Dunleavy, Kieron
Makara, Matt
Carsons, Steven E.
Carteron, Nancy L.
author_facet Lee, Augustine S.
Scofield, R. Hal
Hammitt, Katherine Morland
Gupta, Nishant
Thomas, Donald E.
Moua, Teng
Ussavarungsi, Kamonpun
St Clair, E. William
Meehan, Richard
Dunleavy, Kieron
Makara, Matt
Carsons, Steven E.
Carteron, Nancy L.
author_sort Lee, Augustine S.
collection PubMed
description BACKGROUND: Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren’s syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren’s demonstrate pulmonary involvement with higher mortality and lower quality of life. RESEARCH QUESTION: Clinical practice guidelines for pulmonary manifestations of Sjögren’s were developed by the Sjögren’s Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care. STUDY DESIGN AND METHODS: A rigorous and transparent methodology was followed according to American College of Rheumatology guidelines. The Pulmonary Topic Review Group (TRG) developed clinical questions in the PICO (Patient, Intervention, Comparison, Outcome) format and selected literature search parameters. Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence and strength of recommendation. Guidelines were then drafted based on available evidence, expert opinion, and clinical importance. Draft recommendations with a clinical rationale and data extraction tables were submitted to a Consensus Expert Panel for consideration and approval, with at least 75% agreement required for individual recommendations to be included in the final version. RESULTS: The literature search revealed 1,192 articles, of which 150 qualified for consideration in guideline development. Of the original 85 PICO questions posed by the TRG, 52 recommendations were generated. These were then reviewed by the Consensus Expert Panel and 52 recommendations were finalized, with a mean agreement of 97.71% (range, 79%-100%). The recommendations span topics of evaluating Sjögren’s patients for pulmonary manifestations and assessing, managing, and treating upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease. INTERPRETATION: Clinical practice guidelines for pulmonary manifestations in Sjögren’s will improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists, and pulmonologists. Additionally, opportunities for future research are identified.
format Online
Article
Text
id pubmed-8438162
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American College of Chest Physicians
record_format MEDLINE/PubMed
spelling pubmed-84381622021-09-27 Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s Lee, Augustine S. Scofield, R. Hal Hammitt, Katherine Morland Gupta, Nishant Thomas, Donald E. Moua, Teng Ussavarungsi, Kamonpun St Clair, E. William Meehan, Richard Dunleavy, Kieron Makara, Matt Carsons, Steven E. Carteron, Nancy L. Chest Diffuse Lung Disease: Guideline and Consensus Statement BACKGROUND: Pulmonary disease is a potentially serious yet underdiagnosed complication of Sjögren’s syndrome, the second most common autoimmune rheumatic disease. Approximately 16% of patients with Sjögren’s demonstrate pulmonary involvement with higher mortality and lower quality of life. RESEARCH QUESTION: Clinical practice guidelines for pulmonary manifestations of Sjögren’s were developed by the Sjögren’s Foundation after identifying a critical need for early diagnosis and improved quality and consistency of care. STUDY DESIGN AND METHODS: A rigorous and transparent methodology was followed according to American College of Rheumatology guidelines. The Pulmonary Topic Review Group (TRG) developed clinical questions in the PICO (Patient, Intervention, Comparison, Outcome) format and selected literature search parameters. Each article was reviewed by a minimum of two TRG members for eligibility and assessment of quality of evidence and strength of recommendation. Guidelines were then drafted based on available evidence, expert opinion, and clinical importance. Draft recommendations with a clinical rationale and data extraction tables were submitted to a Consensus Expert Panel for consideration and approval, with at least 75% agreement required for individual recommendations to be included in the final version. RESULTS: The literature search revealed 1,192 articles, of which 150 qualified for consideration in guideline development. Of the original 85 PICO questions posed by the TRG, 52 recommendations were generated. These were then reviewed by the Consensus Expert Panel and 52 recommendations were finalized, with a mean agreement of 97.71% (range, 79%-100%). The recommendations span topics of evaluating Sjögren’s patients for pulmonary manifestations and assessing, managing, and treating upper and lower airway disease, interstitial lung disease, and lymphoproliferative disease. INTERPRETATION: Clinical practice guidelines for pulmonary manifestations in Sjögren’s will improve early identification, evaluation, and uniformity of care by primary care physicians, rheumatologists, and pulmonologists. Additionally, opportunities for future research are identified. American College of Chest Physicians 2021-02 2020-10-16 /pmc/articles/PMC8438162/ /pubmed/33075377 http://dx.doi.org/10.1016/j.chest.2020.10.011 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Diffuse Lung Disease: Guideline and Consensus Statement
Lee, Augustine S.
Scofield, R. Hal
Hammitt, Katherine Morland
Gupta, Nishant
Thomas, Donald E.
Moua, Teng
Ussavarungsi, Kamonpun
St Clair, E. William
Meehan, Richard
Dunleavy, Kieron
Makara, Matt
Carsons, Steven E.
Carteron, Nancy L.
Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title_full Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title_fullStr Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title_full_unstemmed Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title_short Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s
title_sort consensus guidelines for evaluation and management of pulmonary disease in sjögren’s
topic Diffuse Lung Disease: Guideline and Consensus Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438162/
https://www.ncbi.nlm.nih.gov/pubmed/33075377
http://dx.doi.org/10.1016/j.chest.2020.10.011
work_keys_str_mv AT leeaugustines consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT scofieldrhal consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT hammittkatherinemorland consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT guptanishant consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT thomasdonalde consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT mouateng consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT ussavarungsikamonpun consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT stclairewilliam consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT meehanrichard consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT dunleavykieron consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT makaramatt consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT carsonsstevene consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT carteronnancyl consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens
AT consensusguidelinesforevaluationandmanagementofpulmonarydiseaseinsjogrens